A	O
Systematic	B:C1955832
Review	I:C1955832
on	O
Infliximab	B:C0666743
and	O
Adalimumab	B:C1122087
Drug	B:C0085421
Monitoring	I:C0085421
:	O
Levels	O
,	O
Clinical	B:C2985631
Outcomes	I:C2985631
and	O
Assays	B:C1510438
.	O

Immunogenicity	B:C4054739
to	O
therapeutic	O
proteins	O
has	O
been	O
linked	O
to	O
loss	O
of	O
response	O
by	O
a	O
large	O
percentage	O
of	O
patients	O
taking	O
anti-tumor	B:C1562242
necrosis	I:C1562242
factor	I:C1562242
-	I:C1562242
alpha	I:C1562242
agents	I:C1562242
.	O

Drug	B:C0085421
monitoring	I:C0085421
can	O
be	O
extremely	O
useful	O
,	O
allowing	O
physicians	B:C0031831
to	O
adjust	O
the	O
therapeutic	O
scheme	B:C1519193
individually	B:C0237401
.	O

This	O
article	B:C1706852
aims	O
to	O
systematically	B:C1955832
review	I:C1955832
the	O
published	B:C0993637
data	I:C0993637
with	O
respect	O
to	O
cutoff	O
levels	O
of	O
infliximab	B:C0666743
(	O
infliximab	B:C0666743
)	O
and	O
adalimumab	B:C1122087
(	O
adalimumab	B:C1122087
)	O
and	O
relate	O
them	O
to	O
the	O
methodology	O
adopted	O
for	O
quantification	O
of	O
infliximab	B:C0666743
and	O
adalimumab	B:C1122087
levels	O
and	O
clinical	B:C2985631
outcomes	I:C2985631
.	O

The	O
PubMed	B:C1138432
database	I:C1138432
was	O
searched	O
to	O
identify	B:C0020792
studies	B:C2603343
focusing	O
on	O
the	O
association	O
between	B:C0205103
infliximab	B:C0666743
or	O
adalimumab	B:C1122087
cutoff	O
levels	O
and	O
clinical	B:C2985631
outcomes	I:C2985631
in	O
patients	O
with	O
inflammatory	B:C0021390
bowel	I:C0021390
disease	I:C0021390
.	O

Of	O
the	O
1654	O
articles	B:C1706852
initially	O
selected	O
by	O
queries	B:C1522634
,	O
20	O
were	O
included	O
.	O

A	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	B:C0936012
was	O
performed	O
to	O
identify	B:C0020792
cutoff	O
levels	O
of	O
infliximab	B:C0666743
or	O
adalimumab	B:C1122087
that	O
correlated	O
with	O
a	O
clinical	B:C2985631
outcome	I:C2985631
,	O
but	O
only	O
6	O
studies	B:C2603343
performed	O
the	O
same	O
analysis	B:C0936012
for	O
antidrug	B:C3811629
antibody	I:C3811629
levels	O
.	O

Cutoff	O
levels	O
were	O
different	O
between	B:C0205103
studies	B:C2603343
.	O

The	O
methodology	O
chosen	O
for	O
level	O
quantifications	O
,	O
clinical	B:C2985631
outcomes	I:C2985631
,	O
and	O
sample	O
size	O
and	O
characteristics	O
were	O
also	O
different	O
.	O

Nevertheless	O
,	O
measurement	B:C1261153
of	I:C1261153
drug	I:C1261153
levels	I:C1261153
should	O
be	O
performed	O
during	O
maintenance	O
,	O
and	O
with	O
loss	O
of	O
response	O
,	O
with	O
persistent	O
high	O
levels	O
of	O
C	B:C0006560
-	I:C0006560
reactive	I:C0006560
protein	I:C0006560
,	O
and	O
when	O
mucosal	B:C0026724
lesions	B:C0221198
are	O
still	O
present	B:C0150312
.	O

In	O
these	O
scenarios	O
,	O
drug	B:C0013227
and	O
antidrug	B:C0005515
levels	O
were	O
correlated	O
with	O
clinical	B:C2985631
outcomes	I:C2985631
.	O

Concerning	O
drug	B:C0013227
levels	O
monitoring	B:C1283169
any	O
methodology	O
is	O
adequate	O
.	O

With	O
respect	O
to	O
antidrug	B:C3811629
antibody	I:C3811629
levels	O
,	O
it	O
will	O
be	O
necessary	O
to	O
define	O
a	O
gold	O
standard	O
method	B:C0025663
or	O
to	O
establish	O
different	O
cutoff	O
levels	O
for	O
different	O
methodologies	O
.	O

